CIRB Studies

Below is the current list of studies covered by the CIRB. It includes both Available to Open and Completed studies. Study documents approved after July 1, 2013 for all covered studies are available on the CTSU website.

To request documents approved before July 1, 2013, please contact the CIRB Helpdesk.

Displaying 51 - 60 of 1130
Study Number Lead Group Study Title CIRB Study Status
10014 ETCTN A Pilot Study of Atezolizumab (MPDL3280A) Following Adoptive Cell Transfer in Active Hematologic or Solid Tumor Malignancies Adult CIRB - Early Phase Emphasis Available to Open
S1931 SWOG Phase III Trial Of Immunotherapy-Based Combination Therapy With Or Without Cytoreductive Nephrectomy For Metastatic Renal Cell Carcinoma (Probe Trial) Adult CIRB - Late Phase Emphasis Available to Open
9825 ETCTN A Phase 2 Study of Olaparib and Cediranib for the Treatment of Recurrent Ovarian Cancer Adult CIRB - Early Phase Emphasis Available to Open
PEPN2112 COG A Phase 1/ 2 Study of BAY 1895344 (elimusertib, IND#152153, NSC#810486) in Pediatric Patients with Relapsed or Refractory Solid Tumors Pediatric CIRB Available to Open
UAZ20-01-01 CP-CTNet_CLO-University of Arizona Clinical Study of Bioactivity of Low Dose Apalutamide in Prostate Cancer Patients Scheduled for Prostatectomy Cancer Prevention and Control CIRB Available to Open
A041501 Alliance A Phase III Trial to Evaluate the Efficacy of the Addition of Inotuzumab Ozogamicin (A Conjugated Anti-CD22 Monoclonal Antibody) to Frontline Therapy in Young Adults (Ages 18-39 Years) with Newly Diagnosed Precursor B-Cell ALL Adult CIRB - Late Phase Emphasis Available to Open
EA2212 ECOG-ACRIN A Randomized Phase II Study of Perioperative Atezolizumab +/- Chemotherapy in Resectable MSI-H/dMMR Gastric and Gastroesophageal Junction (GEJ) Cancer Adult CIRB - Early Phase Emphasis Available to Open
NRG-DT001 NRG A Phase Ib Trial of Neoadjuvant AMG 232 (KRT-232) Concurrent with Preoperative Radiotherapy in Wild-Type P53 Soft Tissue Sarcoma (STS) Adult CIRB - Early Phase Emphasis Available to Open
NRG-GY018 NRG A Phase III Randomized, Placebo-Controlled Study of Pembrolizumab (MK-3475, NSC #776864) in Addition to Paclitaxel and Carboplatin for Measurable Stage III or IVA, Stage IVB or Recurrent Endometrial Cancer Adult CIRB - Late Phase Emphasis Available to Open
9903 ETCTN A Phase 1B Study of AZD9291 in Combination with Navitoclax in EGFR-mutant Non-Small Cell Lung Cancer Following Resistance to Initial EGFR Kinase Inhibitor Adult CIRB - Early Phase Emphasis Available to Open
Displaying 51 - 60 of 1130